471 related articles for article (PubMed ID: 25801840)
21. Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients.
Nguyen LT; Ramanathan M; Weinstock-Guttman B; Baier M; Brownscheidle C; Jacobs LD
J Neurol Sci; 2003 May; 209(1-2):93-9. PubMed ID: 12686409
[TBL] [Abstract][Full Text] [Related]
22. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
[TBL] [Abstract][Full Text] [Related]
23. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate.
Tumani H; Kassubek J; Hijazi M; Lehmensiek V; Unrath A; Süssmuth S; Lauda F; Kapfer T; Fang L; Senel M; Brettschneider J
Eur Neurol; 2011; 65(3):164-9. PubMed ID: 21372576
[TBL] [Abstract][Full Text] [Related]
24. Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Nischwitz S; Faber H; Sämann PG; Domingues HS; Krishnamoorthy G; Knop M; Müller-Sarnowski F; Yassouridis A; Weber F
Acta Neurol Scand; 2014 Jul; 130(1):46-52. PubMed ID: 24571587
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 17 receptor in multiple sclerosis patients treated with interferon β-1a.
Michałowska-Wender G; Biernacka-Łukanty J; Lasik Z; Jernas L; Wender M
Folia Neuropathol; 2011; 49(2):138-41. PubMed ID: 21845543
[TBL] [Abstract][Full Text] [Related]
26. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
[TBL] [Abstract][Full Text] [Related]
27. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients.
Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G
Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047
[TBL] [Abstract][Full Text] [Related]
28. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
[TBL] [Abstract][Full Text] [Related]
29. Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.
Shokrollahi Barough M; Ashtari F; Sadat Akhavi M; Asghari N; Mosayebi G; Mirmohammadkhani M; Kokhaei N; Bahraminia F; Ajami A; Kokhaei P
Int Immunopharmacol; 2018 Sep; 62():109-113. PubMed ID: 29990690
[TBL] [Abstract][Full Text] [Related]
30. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action.
Balasa RI; Simu M; Voidazan S; Barcutean LI; Bajko Z; Hutanu A; Simu I; Maier S
CNS Neurol Disord Drug Targets; 2017; 16(9):1018-1026. PubMed ID: 28782487
[TBL] [Abstract][Full Text] [Related]
31. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
Phillips JT; Rice G; Frohman E; Vande Gaer L; Scott T; Haas J; Eggenberger E; Freedman MS; Stuart W; Cunha L; Jacobs L; Oger J; Arnold D; Murray TJ; DiBiase M; Jethwa V; Goelz S
Clin Ther; 2004 Apr; 26(4):511-21. PubMed ID: 15189748
[TBL] [Abstract][Full Text] [Related]
32. [Open trial of the effectiveness of interferon beta 1a (Avonex) in the treatment of multiple sclerosis in Poland: MRI results].
Siger-Zajdel M; Lewańska M; Zaleski K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z; Selmaj K
Neurol Neurochir Pol; 2003; 37(6):1185-97. PubMed ID: 15174232
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients.
Lünemann JD; Aktas O; Gniadek P; Zschenderlein R; Zipp F
Neurology; 2001 Sep; 57(6):1132-4. PubMed ID: 11571354
[TBL] [Abstract][Full Text] [Related]
34. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
35. Long-term effect of IFN-beta 1a therapy on CCL2 (MCP-1) chemokine in patients with multiple sclerosis.
Szczuciński A; Losy J
Folia Neuropathol; 2004; 42(1):15-8. PubMed ID: 15119740
[TBL] [Abstract][Full Text] [Related]
36. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
Orefice NS; Alhouayek M; Carotenuto A; Montella S; Barbato F; Comelli A; Calignano A; Muccioli GG; Orefice G
Neurotherapeutics; 2016 Apr; 13(2):428-38. PubMed ID: 26857391
[TBL] [Abstract][Full Text] [Related]
37. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
Khademi M; Wallström E; Andersson M; Piehl F; Di Marco R; Olsson T
J Neuroimmunol; 2000 Mar; 103(2):202-10. PubMed ID: 10696916
[TBL] [Abstract][Full Text] [Related]
38. Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a.
Lanzillo R; Carbone F; Quarantelli M; Bruzzese D; Carotenuto A; De Rosa V; Colamatteo A; Micillo T; De Luca Picione C; Saccà F; De Rosa A; Moccia M; Brescia Morra V; Matarese G
Clin Immunol; 2017 Oct; 183():249-253. PubMed ID: 28823971
[TBL] [Abstract][Full Text] [Related]
39. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
40. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis.
Salama HH; Kolar OJ; Zang YC; Zhang J
Mult Scler; 2003 Feb; 9(1):28-31. PubMed ID: 12617264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
